GlassScriptPhysician profile
Habib Azad
NPI 1114962610
$6,186.43
in general payments reported to CMS, 2019-2025
24 companies · $952 in 2025
The $952 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $655 · 2020: $682 · 2021: $759 · 2022: $910 · 2023: $1,229 · 2024: $999 · 2025: $952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,161 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,161.32 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,092.77 | 2019-2024 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $972.14 | 2019-2025 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $622.05 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $614.00 | 2019-2025 | Velphoro, Korsuva, Velphoro |
| Otsuka America Pharmaceutical, INC. | $504.70 | 2019-2025 | Jynarque |
| Amgen INC. | $410.26 | 2019-2024 | Parsabiv, Aranesp, Tavneos |
| Akebia Therapeutics INC | $305.37 | 2019-2025 | Vafseo |
| Novartis Pharmaceuticals Corporation | $197.90 | 2023-2025 | |
| Ardelyx, INC. | $193.92 | 2024-2025 | Ibsrela |
| Daiichi Sankyo INC. | $178.03 | 2020-2022 | |
| Glaxosmithkline, LLC. | $171.50 | 2021-2023 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.25 | 2024-2025 | Jardiance |
| Travere Therapeutics, INC. | $120.32 | 2023-2025 | |
| Bard Peripheral Vascular, INC. | $117.89 | 2023 | Wavelinq |
| Horizon Therapeutics Plc | $111.60 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $94.59 | 2019-2025 | Ultomiris |
| Opko Pharmaceuticals, LLC | $77.88 | 2019-2020 | |
| Calliditas Therapeutics US INC. | $64.30 | 2022-2024 | |
| Kyowa Kirin, INC. | $56.74 | 2024-2025 | |
| Novo Nordisk INC | $45.19 | 2025 | Ozempic |
| Aurinia Pharma U.S., INC. | $38.05 | 2021-2022 | |
| Lilly USA, LLC | $27.61 | 2025 | Jardiance |
| Mallinckrodt Enterprises LLC | $24.00 | 2019 | |
| Boston Scientific Corporation | $21.37 | 2024 | Wavewriter Alpha Prime 16 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Habib Azad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.